This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bronchopulmonary dysplasia (BPD) of prematurity has emerged as the most common, lethal and expensive neonatal pulmonary disorder in the United States. The pathogenesis of BPD is multi-factorial, has a genetic contribution, and involves injury and inflammation associated with oxygen toxicity and mechanical ventilation in an underdeveloped, immature lung. The estimated prevalence is 30,000 cases/year. Current therapeutic approaches to the prevention and treatment of lung disease in premature infants, including antenatal corticosteroid treatment, replacement surfactant at birth, postnatal administration of corticosteroids, vitamin A, diuretics, caffeine, and bronchodilators have not significantly impacted the overall occurrence of BPD. Recent clinical trials of inhaled nitric oxide (iNO) indicate a beneficial impact on the incidence and severity of BPD as well as short- and long-term safety including 2-year neurodevelopmental outcome. Extremely low birth weight infants (ELBW, defined as ul < ulnone 1000 g and ul < ulnone 30 wk gestation for the purposes of this study) who continue to require mechanical ventilation at 7 d of age have the highest incidence and severity of BPD, which is associated with chronic pulmonary disease and abnormal neurodevelopmental outcome. In recent studies we found that this group of infants has frequent respiratory deteriorations that are associated with dysfunctional pulmonary surfactant and decreased content of surfactant proteins (SP) B and C, which are critical for normal surfactant function to maintain patency of alveoli and terminal airways. Based on these observations, we have performed pilot studies of late administration of SP-B-containing commercial surfactant (Infasurf plain f3 fs18 ). Our preliminary data confirm that the majority of infants still requiring ventilation after 7 d of age have abnormal surface tension measurements and that late doses of surfactant are well tolerated and transiently improve respiratory status. Episodes of surfactant dysfunction also occur among infants receiving iNO. Moreover, surfactant dysfunction in iNO-treated infants is associated with adverse outcome. In this pilot study, we plan to study the addition of late surfactant administration to infants at high risk for BPD who are receiving iNO therapy. HYPOTHESIS We hypothesize that late booster doses of surfactant, in addition to iNO, administered to ELBW infants who continue to require mechanical ventilation between 7 and 14 days of age will significantly decrease the frequency of episodes of surfactant dysfunction in these infants. We further hypothesize that there will be no adverse effects of surfactant treatment on short-term outcomes including death or BPD at 36 weeks postmenstrual age. This pilot trial is being performed to assess the safety and efficacy of late, booster doses of surfactant combined with iNO in ELBW infants at high risk for BPD. This trial is the pilot for a multicenter, randomized controlled trial to assess the effect of late doses of surfactant on the occurrence and severity of BPD in ventilated ELBW infants receiving inhaled Nitric Oxide.
Aim 1. Assess the effect of late doses of surfactant in infants receiving inhaled nitric oxide on frequency of dysfunctional surfactant episodes in ventilated ELBW infants. We will conduct a multi-center placebo-controlled pilot trial of late surfactant treatment in addition to iNO in infants at high risk of BPD. We will enroll 60 infants between 500-1000 g birth weight who are intubated requiring mechanical ventilator support between 7 and 14 d of age. Infants will be treated with either surfactant (Infasurf plain f3 fs18 ) or a sham procedure;study drug treatment will be repeated at intervals up to the fourth week of life if ventilator support is still required. Tracheal aspirate (TA) samples will be collected around each dose of surfactant and iNO dose change for isolation and analysis of surfactant. The trial will have sufficient statistical power to detect a decrease in frequency of episodes of surfactant dysfunction from 50% to 20% in infants receiving combined therapy. In addition, data will be obtained related to the duration of efficacy of administered surfactant in infants >1 week of age.
Aim 2. Assess effects of late surfactant treatment on the respiratory status of ventilated ELBW infants b0 . We will collect clinical data to investigate effects of surfactant treatment on both short-term respiratory support need, as assessed by the Respiratory Severity Score (RSS), and pulmonary status at 36 weeks'PMA (survival without BPD). We also will monitor for evidence of toxicity as indicated by any of the known complications of surfactant administration as well as by the occurrence and severity of other common morbidities of preterm infants, including intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL), patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC) and retinopathy of prematurity (ROP). We expect that combined iNO-surfactant therapy will be safe. We will determine the relationship between surfactant function (Aim 1) and both short-term respiratory status and 36-week outcome.
Showing the most recent 10 out of 459 publications
